Anti cd11c

BMDCs were incubated with APG@OVA NPs for 24 h, then collected and resuspended in 1640 medium. Afterward, the cell samples (2 x 10⁶ cells) were injected into C57BL/6 mice at the left hind leg footpads. After injection, MRI scanning was carried out under a 3.0 T clinical MRI scanner at different time points (0, 24, 48 and 72 h) to monitor the DCs migration process, with T₁-weighted fast spin-echo sequence (FA = 111°; TR/TE = 360/10 ms; slice thickness = 1 mm without gap). Then the mice were sacrificed post-injection of the APG@OVA NPs labeled-DCs for 72 h and the left inguinal lymph nodes of mice were cut out. Subsequently, lymph nodes were sliced for Raman mapping, and immunohistochemical staining (anti-CD11c (Servicebio) was used to stain DCs in the lymph nodes). Raman mapping was performed by a Raman confocal microscope with a 633 nm laser, a power of 3 mW, a 50× objective lens, and the exposure time was 1 s.
To assess the distribution of the labeled-BMDCs in different organs in vivo, APG@OVA NP-labeled BMDCs (2 × 10⁶ cells / 50 µL) were intravenously injected into C57BL/6 mice to follow and detect BMDCs. After injection, MRI scanning was carried out under a 3.0 T clinical MRI scanner at different time points (1, 3, 4, and 24 h) to monitor the DCs.

Tissues fixed with paraformaldehyde overnight were embedded in paraffin and sliced in sections of 5 µm thickness. Sections were dewaxed in xylole and rehydrated in graded alcohol in preparation for immunohistochemistry (IHC). IHC was performed as per the previous study [29 (link)]. The primary antibody of M1 macrophage marker, anti-CD11c (Servicebio, Wuhan, China), was used. Images of the paraffin section of the jejunum were obtained using a Leica DM3000 Microsystem (Leica Camera AG, Wetzlar, Germany).